Login to Your Account

Streamlining Astellas ditches long-listed products in LTL deal

By Kohei Kanayasu
Staff Writer

Monday, May 15, 2017

TOKYO – Astellas Pharma Inc. is streamlining its product lineup by selling off rights to 16 of its long-listed products to LTL Pharma Co. Ltd. in a deal worth ¥20.1 billion, a move that will enable Astellas to focus on newer and more profitable drugs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription